L26/O-159 Preimplantation genetic testing for aneuploidy in POSEIDON Group 4: benefit or harm?
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von X. Liu.
Abstract (Originalsprache)
Study question To investigate whether preimplantation genetic testing for aneuploidy (PGT-A) benefits women classified in POSEIDON Group 4. Summary answer PGT-A did not improve pregnancy/live birth rates but reduced miscarriage rates vs non-PGT-A. What is known already ART use rises in advanced-age women, with embryos prone to chromosomal abnormalities and poor outcomes. PGT-A benefits some but lacks data in POSEIDON Group 4 (≥35y, low AFC/AMH). These patients have few oocytes/blastocysts; PGT-A may reduce miscarriage but risks cycle failure, creating clinical dilemmas. Study design, size, duration This retrospective PSM cohort study included 54,122 POSEIDON Group 4 women undergoing first IVF (2020–2024). PGT-A and non-PGT-A groups were matched 1:3. Outcomes: biochemical/clinical pregnancy, miscarriage, ectopic pregnancy, live birth rates per transfer/retrieval. Participants/materials, setting, methods PGT-A (trophectoderm biopsy + NGS) and non-PGT-A groups were 1:3 PSM-matched. Outcomes (per transfer/retrieval): biochemical/clinical pregnancy, miscarriage, ectopic pregnancy, live birth rates (analyzed via SPSS, RRs + 95% CIs). Main results and the role of chance PGT-A had comparable biochemical pregnancy per transfer (risk ratio [RR]: 0.75, 95% confidence interval [95% CI], 0.43-1.18) and per retrieval (RR: 0.75, 95% CI, 0.41-1.19). While PGT-A group also had similar clinical pregnancy per transfer (RR: 0.75, 95% CI, 0.36-1.20) and per retrieval (RR: 0.75, 95% CI, 0.38-1.23), they achieved significantly lower miscarriage per transfer (RR: 0.17, 95% CI, 0.00-0.59) and per retrieval (RR: 0.17, 95% CI, 0.00-0.58). However, live birth rates were similar both in per transfer (RR: 0.89, 95% CI, 0.35-1.65) and per retrieval (RR: 0.89, 95% CI, 0.39-1.69). Limitations, reasons for caution Retrospective design limits causal inference. Potential unmeasured confounders exist. Generalizability may be restricted to POSEIDON Group 4 women at tertiary centers. Wider implications of the findings For POSEIDON Group 4 patients, PGT-A reduces miscarriage risk without improving live birth rates, offering evidence-based guidance for personalized ART decision-making in this high-risk subgroup. Trial registration number No
Zitieren
APA
Liu, X. (2026). L26/O-159 Preimplantation genetic testing for aneuploidy in POSEIDON Group 4: benefit or harm?. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.157
Vancouver
Liu X. L26/O-159 Preimplantation genetic testing for aneuploidy in POSEIDON Group 4: benefit or harm?. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.157
BibTeX
@article{Liu2026,
author = {Liu, X.},
title = {L26/O-159 Preimplantation genetic testing for aneuploidy in POSEIDON Group 4: benefit or harm?},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.157}
}
EUVIMED